A Process For Preparing (S) 6 Chloro ( Cyclopropylethynyl) 1 ,4 Dihydro 4 (Trifluoromethyl) 2 H 3, 1 Benzoxazin 2 One Polymorphic Form P,

Matrix Laboratories Limited
Granted App No 3080/CHE/2007 Patent 294029 Chemical

Patent information

IP India · live record
Application number
3080/CHE/2007
Filing date
24 December 2007
Status
Granted
Legal status
Ceased
Publication number
37/2009
Publication type
INA
Invention field
Chemical
Patent number
294029
Grant date
09 March 2018
Next renewal due
24 December 2020Overdue

Abstract

Invention Disclosed herein is a novel process for preparing polymorphic Forms of (S)-6-chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1 -benzoxazin-2-one referred as Ml, I, II, β, and ω.

Applicants

1
India
MATRIX LABORATORIES LIMITED 1-1-151/1, 4TH FLOOR SAI RAM TOWERS ALEXANDER ROAD SECUNDERABAD 500 003

Inventors

3
India
TYAGI, OM DUTTC/O MATRIX LABORATORIES LIMITED PLOT NO 34 A, ANRICH INDUSTRIAL ESTATE BOLLARAM, JINNARAM MANDAL-502 325 MEDAK DIST, ANDHRA PRADESH
India
JETTI, RAM, K, RC/O MATRIX LABORATORIES LIMITED PLOT NO 34 A ANRICH INDUSTRIAL ESTATE BOLLARAM, JINNARAM MANDAL-502 325 MEDAK DIST, ANDHRA PRADESH
India
RAMIREDDY, B.AC/O MATRIX LABORATORIES LIMITED PLOT NO 34 A ANRICH INDUSTRIAL ESTATE BOLLARAM, JINNARAM MANDAL-502 325 MEDAK DIST, ANDHRA PRADESH

Claims

9
1 A process for preparing (S)-6-chloro-(cyclopropylethynyl)-l,4-dihydro-4- (trifluoromethyl)-2H-3,l-benzoxazin-2-one polymorphic Form R, comprising: dissolving efavirenz in a solvent, cooling the reaction mass followed by seeding the resultant, adding anti-solvent and isolating the pure polymorphic Form 6 of (S)-6-chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1 -benzoxazin-2-one.
2 The process according to claim 1, wherein the step of dissolving efavirenz in the solvent is carried out preferably at room temperature
3 The process according to claim 1, wherein solvent used is selected from the group consisting of lower aliphatic alcohols, lower aliphatic carboxylic acids, hetero aromatics, polar aprotic solvents, esters, aliphatic hydrocarbons, or mixtures thereof with water.
4 The process according to claim 3, wherein the solvent is selected from methanol, ethanol, isopropyl alcohol, formic acid, acetic acid, ethyl acetate, isopropyl acetate, dimethylformamide , 1 -methyl-2-pyrrolidinone or mixtures thereof
5 The process according to claim 1, wherein the reaction mass is cooled to 0-10°C, preferably to 0-5°C.
6 The process according to claim 1, wherein the anti-solvent used is selected from water, n-heptane or mixtures thereof
7 A process for preparing (S)-6-chloro-(cyclopropylethynyl)-l,4-dihydro-4-(trifluoromethyl)-2H-3,l-benzoxazin-2-one polymorphic Form B, comprising: dissolving the efavirenz in a mixture of water and water miscible organic solvent, removing the solvent and isolating the polymorphic Form C of efavirenz.
8 The process according to claim 7, wherein water the miscible organic solvent is selected from methanol, ethanol, isopropyl alcohol, acetone or mixtures thereof.
9 The process according to claim 8, wherein the solvent is removed by employing freeze drying or distillation method.

Specification

Show full textCollapse

Field of the Invention This invention, in general, relates to a process for preparing polymorphic forms of (S)-6-chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1 -benzoxazin-2-one (Efavirenz). More particularly, the present invention provides a novel process for preparing polymorphic Forms of efavirenz referred as Mi, I, II, β, and ω. Background of the Invention Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission. Efavirenz, is chemically described as (S)-6-chloro-(cyclopropylethynyl)-l,4-dihydro-4-(trifluoromethyl)-2H-3,l-benzoxazin-2-one, having the following structure:

Efavirenz product is first claimed in US 5,519,021. The process disclosed in this patent involves reaction of racemic Efavirenz with optically active acid derivative followed by repeated purifications to give diastereomer. It is further subjected to hydrolysis in the presence of acid in n-butanol to give crude Efavirenz which is then recrystallized from

hexane to give pure Efavirenz. However, this patent does not disclose any polymorphic forms of Efavirenz. US patents 6,939,964 and 6,639,071 claimed crystalline efavirenz polymorphic Forms I, II and III. US 6,673,372 patent disclosed the crystalline efavirenz polymorphic Forms 1, 2, 3, 4 & 5. US 2006/0235008 claims different crystalline and amorphous forms of Efavirenz and process for the preparation thereof WO 2006/040643 application further discloses Efavirenz polymorphic Forms a, P, y, yl, Y2, CO, 5, N, O, P and processes for their preparation. The reproduction of examples for these polymorphs as disclosed in WO '643 is found to be very inconsistent. Also, it was found that some of these forms were never reproduced in our laboratory. In light of above disadvantages in prior art processes, there is a need to prepare the pure and stable Efavirenz polymorphic forms by an efficient, economic and reproducible process, particularly to large scale preparation. Further, it should be suitable for handling and should have excellent physical and chemical stability, mainly to different heat and humidity conditions. Summary of the Invention In accordance with prinicipal aspect of the present invention, there is provided a novel process for preparing polymorphic Forms of efavirenz, referred as Mi, I, II, P, and co, wherein said process enables to achieve high purity and stability of said polymorphic forms. In accordance with one preferred embodiment of the present invention, there is provided a novel process for preparing a polymorphic Form 6 of (S)-6-chloro-(cyclopropylethynyl)-l,4-dihydro-4-(trifIuoromethyl)-2H-3,l-benzoxazin-2-one (Efavirenz), wherein the process comprises of dissolving efavirenz in a solvent, cooling the reaction mass followed by seeding the resultant, adding anti-solvent and isolating the pure efavirenz polymorphic Form 13. In accordance with another preferred embodiment of the present invention, there is provided a novel process for preparing a polymorphic Form R of (S)-6-chloro-(cyclopropylethynyl)-l,4-dihydro-4-(trifluoromethyl)-2H-3,l-benzoxazin-2-one (Efavirenz), wherein the process

comprises of dissolving the efavirenz in a mixture of water and water miscible organic solvent, removing the solvent and isolating the efavirenz polymorphic Form B, wherein the solvent is removed by employing freeze drying or distillation method. Brief Description of the Drawings: Further objects of the present invention together with additional features contributing thereto and advantages accruing there from will be apparent from the following description of preferred embodiments of the invention which are shown in the accompanying drawing figures, wherein: Figure 1: X-ray powder diffraction pattern of Efavirenz Form Mi Figure 2: DSC of Efavirenz Form Mi Detailed Description of the Invention While this specification concludes with claims particularly pointing out and distinctly claiming that, which is regarded as the invention, it is anticipated that the invention can be more readily understood through reading the following detailed description of the invention and study of the included examples. The disclosed embodiment of the present invention deals with a novel and consistent process for preparing polymorphic forms of (S)-6-chloro-(cyclopropylethynyl)-l,4-dihydro-4-(trifluoromethyl)-2H-3,l-benzoxazin-2-one, referred as Form I, Form II, Form p and Form co. The present invention also discloses a novel polymorphic form of (S)-6-chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1 -benzoxazin-2-one, refered as Form Ml and process for preparing said polymorphic form. According to the present invention, the polymorphs disclosed herein are ftirther characterized by X-ray powder diffraction pattern (XRD), Thermogravimetric Analysis (TGA), Differential Scanning Calorimetry (DSC), and/or moisture content (MC).

Powder X-rav Diffraction (PXRD) The PXRD measurements were carried out using PANalytical, X'Pert PRO powder diffractometer equipped with goniometer of 0/0 configuration and X'Celerator detector. The Cu-anode X-ray tube was operated at 40kV and 30mA. The experiments were conducted over the 29 range of 2.0°-50.0°, 0.030° step size and 50 seconds step time. Differential Scanning Calorimetrv (DSC) The DSC measurements were carried out on Mettler Toledo 822 Star* instrument. The experiments were performed at a heating rate of 10.0°C/minute over a temperature range of 30°C-200°C purging with nitrogen at a flow rate of 50ml/minute. Standard aluminum crucibles covered by lids with three pin holes were used. According to the present invention the novel polymorphic form Mi of efavirenz is characterized by PXRD as shown in Figure 1 and DSC as shovra in Figure 2. The present invention provides a novel process for preparing polymorphic Form Mi of efavirenz, wherein said process comprises of dissolving efavirenz in a suitable solvent at a temperature range between 20-30°C, preferably at 25-30°C, cooling the resultant to 0-10°C, preferably 0-5°C followed by the addition of water and isolating the efavirenz Form Mi. The solvent used herein for dissolution is selected from a group consisting of formic acid, pyridine or mixtures thereof with water. In another embodiment, the present invention provides a process for preparing polymorphic Form I of efavirenz, wherein the process comprises of heating crystalline efavirenz Form Mi at 70-80°C under vaccum for several hours to obtain Form I of efavirenz. In another embodiment of the present invention, there is provided a process for preparing polymorphic Form I of efavirenz, wherein said process comprises of dissolving efavirenz in a solvent selected from the group consisting of lower aliphatic carboxylic acids, chlorinated solvents, hetero-aromatics, esters, or mixtures thereof, preferably selected from acetic acid, dichloromethane (DCM), pyridine, ethyl acetate or mixtures thereof with water followed by addition of n-heptane, water or mixtures thereof and recovering the crystalline efavirenz

Form I using different crystallization methods like anti-solvent or slow or fast crystallization or by distillation method. The present invention also provides a process for preparing Form II of efavirenz, wherein said process comprises of dissolving efavirenz in n-butanol, cooling the resultant to 0-5°C followed by addition of water to obtain efavirenz Form II. Further embodiment of the present invention provides a novel process for preparing polymorphic Form B of efavirenz, wherein the process comprises of dissolving efavirenz in a solvent at room temperature, cooling the resultant solution followed by seeding the resultant solution, adding anti-solvent and isolating the pure efavirenz polymorphic Form B. The temperature used herein for dissolving the efavirenz is in the range of 20-30°C, preferably 25-30°C. The clear solution is then cooled to 0-10°C, preferably to 0-5°C and then seeded (-4%) with efavirenz Form P in lots, preferably in 1-3 lots. The antisolvent is then added to the above solution over a period of 1-3 hours. The precipitated solid is filtered and dried to obtain polymorphic Form p of efavirenz. According to the present invention, the solvent used herein for the preparation of P form of efavirenz is selected from the group comprising lower aliphatic alcohols, lower aliphatic carboxylic acids, hetero aromatics, polar aprotic solvents, esters, aliphatic hydrocarbons, or mixtures thereof with water, preferably methanol (MeOH), ethanol (EtOH), isopropyl alcohol (IPA), formic acid, acetic acid, ethyl acetate (EtOAc), isopropyl acetate, dimethylformamide (DMF), l-methyl-2-pyrrolidinone (NMP). According to the present invention, the anti solvent is selected from n-heptane, water or mixtures thereof In an alternative embodiment of the present invention, the P form of efavirenz is prepared by a process comprising of dissolving efavirenz in a mixture of acetone/water or methanol/water followed by lyophilization or freeze-drying. The p form of efavirenz, according to the present invention, can also be prepared by slurring Form MI in heptane, Isopropyl ether (IPE), water or mixture thereof at ambient temperature for several hours.

The P form of efavirenz can also be prepared by exposing Form Mi to relative humidity (RH>90%) at ambient temperature for several hours at ambient temperature. According to the present invention the P form of efavirenz is prepared consistently by above said processes having higher purity and stability under different heat and humid conditions. In another embodiment, the present invention provides a process for preparing polymorphic Form CD of efavirenz, wherein the process comprises of dissolving efavirenz in a mixture of methanol and water followed by lyophilization or freeze-drying. In the foregoing, embodiments are described by way of below examples to illustrate the process of invention. However, these are not intended in any way to limit the scope of the present invention and several variants of these examples would be evident to person ordinarily skilled in the art. Example 1 Preparation of polvmorphic Form M^ of efavirenz Efavirenz (3 g) was dissolved in formic acid (30 ml) and the resulting clear solution was cooled to about 0-5°C, stirred for 30 min. Then added 400 ml of DM Water slowly and maintained at 0-5°C, then filtered and dried at ambient temperature. The resuhing crystalline solid was identified as Efavirenz Form Mi. XRD of the dried sample showed it to be Form Mi Example 2 Preparation of polvmorphic Form Mi^ of efavirenz Efavirenz (3 g) was dissolved in pyridine (20 ml) and the resulting clear solution was cooled to about 0-5°C, stirred for 30 min. Then 400 ml of DM Water was added slowly and maintained for 1 hr at 0-5°C, then filtered and dried-at ambient temperature. The resulting crystalline solid was identified as Efavirenz Form Mi. XRD of the dried sample showed it to be Form Mi.

Example 3 Preparation of p form of efavirenz: 2 g Efavirenz was dissolved in indicated solvents at the indicated volumes at 50-60°C. The resulting solution is then filtered through hy-flow bed to remove undissolved particulate. The resulting clear solution was then subjected to fi-eeze drying (Model: Virtis Genesis SQ Freeze Dryer) at -104°C and below 200 Torr vacuum. The results are shown in following Table 1. Table 1

Input

Solvents

Volume ratio (v/v) Resuh

Efavirenz

Water: Acetone Water: Methanol Methanol

1:1.25 1:1.5 1:5

Form p

Example 4 Preparation of p form of efavirenz: 3g of Efavirenz was dissolved in indicated solvents at the indicated volumes at 25-30°C and stirred for 30 min. The resulting solution was cooled to 0-5°C and an indicated anti solvent at the indicated volumes are added slowly. The resulting reaction mass was stirred at 0-5 °C. The solid is filtered and washed with 5 ml of indicated solvents. The wet solid was dried at 25-30°C. The results are shovm in following Table 2. Table 2

Input Process Antisolvent Efavirenz

Solvents Volume ratio (v/v) PXRD Result Acetic acid: water DMF : water NMP : water 1:20 1:14 1:14 Form p

Example 5 Preparation of P form of efavirenz: Efavirenz (3 g) is suspended in Ethyl acetate (30 ml) at room temperature. Stir for 15 min to get clear solution. Filtered through cotton and cooled the solution to 0-5°C. Seeds added to the clear solution at 0-5°C. To this solution n-heptane (400 ml) added in two lots, with addition of second lot of the seeds and stirred for 30 min at 0-5°C. Distilled to half of the volume, then cooled to 0-5°C and maintained for 1 hour. Solid material formed was filtered and air-dried. The solid obtained was identified as Efavirenz Form p. XRD of the dried sample showed it to be Form p Example 6 Preparation of P form of efavirenz: Efavirenz (5 g) is suspended in methanol (50 ml) at room temperature. Stir for 15 min to get clear solution. Filtered through cotton and cooled the solution to 0-5°C. Seeds of form-P (approx. 4%) in two lots added to the clear solution and stirred for 30 min at 0-5°C. Added lU of water in two lots; first 25 ml of water added to the solution at 0-5°C, followed by third lot of form P seeds under stirring. Added remaining water in 1-2 hour and maintained for 2 hours at 0-5°C. The solid material formed was filtered at 0-5°C. The solid obtained was identified as Efavirenz Form p. XRD showed it to be Form P Example 7 Preparation of Form I of Efavirenz: 1 g of Efavirenz Form Mi obtained as described above was kept in a static dryer and heated at 80°e under vacuum for 15 hr. The resulting solid was identified as Efavirenz Form I. XRD showed it to be Form I Example 8 Preparation of Form I of Efavirenz: Taken 3 g of Efavirenz in formic acid (30 ml) and heated to 80°C to obtain a clear solution. Cooled to room temperature and added water (100 ml) slowly for 15-30 min and maintained for 36 hrs at Room Temperature (RT) with agitation. The resulting white free flowing solid was filtered and identified as Efavirenz Form I.

XRD showed it to be Form I Example 9 Preparation of Form I of efavirenz: Taken Efavirenz (1 g) in pyridine (2 ml) and filtered to remove imdissolved particulate. The resulting solution was kept in Petri dish for aerial drying. The solid obtained was identified as Efavirenz Form I. XRD showed it to be Form I Example 10 Preparation of Form I of efavirenz: Taken Efavirenz (1 g) in dichloromethane (25 ml) at room temperature and the resulting clear solution was distilled completely under vacuum. The solid obtained was identified as Efavirenz Form I. XRD showed it to be Form I Example 11 Preparation of Form I of efavirenz: Taken Efavirenz (3 g) in ethyl acetate (30 ml) and stirred for 15-30 min at room temperature. To the resulting solution added n-heptane (300 ml) and stirred for 1 hr at room temperature. The resulting clear solution was distilled half of the volume of reaction mass and cooled to room temperature and filtered. The obtained solid was identified as Efavirenz Form I. XRD showed it to be Form I Example 12 Preparation of Form II of efavirenz: Taken 3 g of Efavirenz in n-butanol (30 ml) and the resulting clear solution was filtered though hy-flow bed to remove undissolved particulate. The solution was cooled to 0-5°C, added water (400 ml) maintained for 1 hr and filtered. The obtained solid was identified as Efavirenz Form II. XRD showed it to be Form II

While this invention has been described in detail with reference to certain preferred embodiments, it should be appreciated that the present invention is not limited to those precise embodiments rather, in view of the present disclosure, which describes the current best mode for practicing the invention, many modifications and variations, would present themselves to those skilled in the art without departing from the scope and spirit of this invention. This invention is susceptible to considerable variation in its practice within the spirit and scope of the appended claims.

We Claim: 1. A process for preparing (S)-6-chloro-(cyclopropylethynyl)-l,4-dihydro-4- (trifluoromethyl)-2H-3,l-benzoxazin-2-one polymorphic Form R, comprising: dissolving efavirenz in a solvent, cooling the reaction mass followed by seeding the resultant, adding anti-solvent and isolating the pure polymorphic Form 6 of (S)-6-chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1 -benzoxazin-2-one. 2. The process according to claim 1, wherein the step of dissolving efavirenz in the solvent is carried out preferably at room temperature 3. The process according to claim 1, wherein solvent used is selected from the group consisting of lower aliphatic alcohols, lower aliphatic carboxylic acids, hetero aromatics, polar aprotic solvents, esters, aliphatic hydrocarbons, or mixtures thereof with water. 4. The process according to claim 3, wherein the solvent is selected from methanol, ethanol, isopropyl alcohol, formic acid, acetic acid, ethyl acetate, isopropyl acetate, dimethylformamide , 1 -methyl-2-pyrrolidinone or mixtures thereof 5. The process according to claim 1, wherein the reaction mass is cooled to 0-10°C, preferably to 0-5°C. 6. The process according to claim 1, wherein the anti-solvent used is selected from water, n-heptane or mixtures thereof 7. A process for preparing (S)-6-chloro-(cyclopropylethynyl)-l,4-dihydro-4-(trifluoromethyl)-2H-3,l-benzoxazin-2-one polymorphic Form B, comprising: dissolving the efavirenz in a mixture of water and water miscible organic solvent, removing the solvent and isolating the polymorphic Form C of efavirenz. 8. The process according to claim 7, wherein water the miscible organic solvent is selected from methanol, ethanol, isopropyl alcohol, acetone or mixtures thereof.

9. The process according to claim 8, wherein the solvent is removed by employing freeze drying or distillation method.

Documents

Sign in to open
Orders
Section 15(Grant)Controller: Rajendra Lohiya 09 Mar 2018
Section 15(Grant)Controller: Rajendra Lohiya 09 Mar 2018
Application documents
1 3080-che-2007 form-3 12-07-2010.pdf 12 Jul 2010
2 3080-che-2007 form-3 28-07-2010.pdf 28 Jul 2010
3 3080-che-2007-form 5.pdf 04 Sep 2011
4 3080-che-2007-form 3.pdf 04 Sep 2011
5 3080-che-2007-form 1.pdf 04 Sep 2011
6 3080-che-2007-drawings.pdf 04 Sep 2011
7 3080-che-2007-description(provisional).pdf 04 Sep 2011
8 3080-che-2007-correspondnece-others.pdf 04 Sep 2011
9 3080-che-2007 form-5.pdf 04 Sep 2011
10 3080-che-2007 form-3.pdf 04 Sep 2011
11 3080-che-2007 form-26.pdf 04 Sep 2011
12 3080-che-2007 form-1.pdf 04 Sep 2011
13 3080-che-2007 drawings.pdf 04 Sep 2011
14 3080-che-2007 description (complete).pdf 04 Sep 2011
15 3080-che-2007 correspondence-others.pdf 04 Sep 2011
16 3080-che-2007 claims.pdf 04 Sep 2011
17 3080-che-2007 abstract.pdf 04 Sep 2011
18 3080-CHE-2007 FORM-18 19-12-2011.pdf 19 Dec 2011
19 3080-CHE-2007 CORRESPONDENCE OTHERS 19-12-2011.pdf 19 Dec 2011
20 3080-CHE-2007 FORM-3 06-12-2012.pdf 06 Dec 2012
21 3080-CHE-2007 FORM-5 30-09-2013.pdf 30 Sep 2013
22 3080-CHE-2007 FORM-2 30-09-2013.pdf 30 Sep 2013
23 3080-CHE-2007 FORM-13 30-09-2013.pdf 30 Sep 2013
24 3080-CHE-2007 FORM-1 30-09-2013.pdf 30 Sep 2013
25 3080-CHE-2007 CORRESPONDENCE OTHERS 30-09-2013.pdf 30 Sep 2013
26 3080-CHE-2007-FER.pdf 31 Jan 2017
27 Other Document [21-03-2017(online)].pdf 21 Mar 2017
28 Form 13 [21-03-2017(online)].pdf 21 Mar 2017
29 3080-CHE-2007-PETITION UNDER RULE 137 [26-07-2017(online)].pdf 26 Jul 2017
30 3080-CHE-2007-FER_SER_REPLY [26-07-2017(online)].pdf 26 Jul 2017
31 3080-CHE-2007-COMPLETE SPECIFICATION [26-07-2017(online)].pdf 26 Jul 2017
32 3080-CHE-2007-HearingNoticeLetter.pdf 08 Sep 2017
33 3080-CHE-2007-Correspondence to notify the Controller (Mandatory) [24-10-2017(online)].pdf 24 Oct 2017
34 3080-CHE-2007-Written submissions and relevant documents (MANDATORY) [03-11-2017(online)].pdf 03 Nov 2017
35 3080-CHE-2007-ExtendedHearingNoticeLetter_21Dec2017.pdf 10 Nov 2017
36 3080-CHE-2007-Written submissions and relevant documents (MANDATORY) [08-03-2018(online)].pdf 08 Mar 2018
37 Marked up Claims_Granted 294029_09-03-2018.pdf 09 Mar 2018
38 Drawings_Granted 294029_09-03-2018.pdf 09 Mar 2018
39 Description_Granted 294029_09-03-2018.pdf 09 Mar 2018
40 Claims_Granted 294029_09-03-2018.pdf 09 Mar 2018
41 Abstract_Granted 294029_09-03-2018.pdf 09 Mar 2018
42 3080-CHE-2007-PatentCertificate09-03-2018.pdf 09 Mar 2018
43 3080-CHE-2007-IntimationOfGrant09-03-2018.pdf 09 Mar 2018
44 3080-CHE-2007-RELEVANT DOCUMENTS [30-03-2018(online)].pdf 30 Mar 2018
45 3080-CHE-2007-RELEVANT DOCUMENTS [19-03-2019(online)].pdf 19 Mar 2019
46 3080-CHE-2007-RELEVANT DOCUMENTS [30-03-2020(online)].pdf 30 Mar 2020
Search strategy
13080srchstr_31-01-2017.pdf

ERegister / renewals

Ceased
3rd Renewed 15 Mar 2018 Period 24 Dec 2009 – 24 Dec 2010 · CBR 7191 · Certificate 9454 ₹4,000
4th Renewed 15 Mar 2018 Period 24 Dec 2010 – 24 Dec 2011 · CBR 7191 · Certificate 9455 ₹4,000
5th Renewed 15 Mar 2018 Period 24 Dec 2011 – 24 Dec 2012 · CBR 7191 · Certificate 9456 ₹4,000
6th Renewed 15 Mar 2018 Period 24 Dec 2012 – 24 Dec 2013 · CBR 7191 · Certificate 9457 ₹4,000
7th Renewed 15 Mar 2018 Period 24 Dec 2013 – 24 Dec 2014 · CBR 7191 · Certificate 9458 ₹12,000
8th Renewed 15 Mar 2018 Period 24 Dec 2014 – 24 Dec 2015 · CBR 7191 · Certificate 9459 ₹12,000
9th Renewed 15 Mar 2018 Period 24 Dec 2015 – 24 Dec 2016 · CBR 7191 · Certificate 9460 ₹12,000
10th Renewed 15 Mar 2018 Period 24 Dec 2016 – 24 Dec 2017 · CBR 7191 · Certificate 9461 ₹12,000
11th Renewed 15 Mar 2018 Period 24 Dec 2017 – 24 Dec 2018 · CBR 7191 · Certificate 9462 ₹24,000
12th Renewed 05 Dec 2018 Period 24 Dec 2018 – 24 Dec 2019 · CBR 34901 · Certificate 41380 ₹24,000
13th Renewed 09 Dec 2019 Period 24 Dec 2019 – 24 Dec 2020 · CBR 40547 · Certificate 57308 ₹24,000